SCHEMBL1339189

SCHEMBL1339189

CCOCc1nc(-c2ccc3c(c2)c2cc(-c4ccc(Cl)cc4Cl)c(=O)n(C)c2n3C)co1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 4/20 0.41
▸ GABRG2 P18507 2/20 0.41
▸ GABRB3 P28472 2/20 0.41
▸ GABRA5 P31644 2/20 0.41
▸ KDM4E B2RXH2 3/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ GAA P10253 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MAPT P10636 2/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34
▸ CNR1 P21554 13/20 0.33
▸ CNR2 P34972 12/20 0.33
▸ RIPK2 O43353 1/20 0.32
▸ NOD2 Q9HC29 1/20 0.32
▸ ADRA2C P18825 2/20 0.32
▸ SLC6A3 Q01959 2/20 0.32
▸ EGFR P00533 1/20 0.32
▸ ALOX5 P09917 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339478 0.88 CNR1 (0.39) GABRA1KDM4EALDH1A1GAAHPGD
SCHEMBL1339526 0.86 CNR1 (0.36) GABRA1GABRG2GABRB3GABRA5KDM4E
SCHEMBL1336863 0.84 KDM4E (0.39) GABRA1KDM4EALDH1A1GAAHPGD
SCHEMBL1337288 0.84 GABRA1 (0.41) GABRA1GABRG2GABRB3GABRA5KDM4E
SCHEMBL1337046 0.84 GABRG2 (0.42) GABRA1GABRG2GABRB3GABRA5KDM4E
SCHEMBL1339390 0.83 CNR1 (0.40) GABRA1KDM4EALDH1A1GAAHPGD
SCHEMBL3250019 0.83 KDM4E (0.39) GABRA1KDM4EALDH1A1GAAHPGD
SCHEMBL1338687 0.80 GABRA1 (0.39) GABRA1GABRG2GABRB3GABRA5KDM4E
SCHEMBL1338722 0.80 GABRA1 (0.42) GABRA1GABRG2GABRB3GABRA5KDM4E
SCHEMBL1338637 0.80 GABRA1 (0.38) GABRA1GABRG2GABRB3GABRA5KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 GABRA1 1457/4885GABRG2 1617/4885GABRB3 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback